FDA Awards Priority Review Voucher to Alexion Pharmaceuticals for Rare Pediatric Disease Product STRENSIQ

Summary

The US Food and Drug Administration (FDA) has announced the issuance of a priority review voucher to Alexion Pharmaceuticals, Inc. for its rare pediatric disease product STRENSIQ, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Food and Drug Administration Safety and Innovation Act (FDASIA).